These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17407132)

  • 21. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
    Wong JC; Tang G; Wu X; Liang C; Zhang Z; Guo L; Peng Z; Zhang W; Lin X; Wang Z; Mei J; Chen J; Pan S; Zhang N; Liu Y; Zhou M; Feng L; Zhao W; Li S; Zhang C; Zhang M; Rong Y; Jin TG; Zhang X; Ren S; Ji Y; Zhao R; She J; Ren Y; Xu C; Chen D; Cai J; Shan S; Pan D; Ning Z; Lu X; Chen T; He Y; Chen L
    J Med Chem; 2012 Oct; 55(20):8903-25. PubMed ID: 23061376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
    Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
    Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.
    Ganslmayer M; Konturek P; Herold C; Neurath MF; Zopf S
    Anticancer Res; 2012 Dec; 32(12):5263-9. PubMed ID: 23225425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine.
    Fan H; Zhao ZJ; Cheng YC; Shan YF; Lu ZH; Zhang JQ; Xie W
    Chin Med J (Engl); 2007 Sep; 120(18):1626-31. PubMed ID: 17908484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
    Egger G; Aparicio AM; Escobar SG; Jones PA
    Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
    Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
    Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
    Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
    Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
    Kanda T; Tada M; Imazeki F; Yokosuka O; Nagao K; Saisho H
    Oncol Rep; 2005 Oct; 14(4):975-9. PubMed ID: 16142360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased PADI4 mRNA association with global hypomethylation in hepatocellular carcinoma during HBV exposure.
    Zhang C; Fan L; Fan T; Wu D; Gao L; Ling Y; Zhu J; Li R; Wei L
    Cell Biochem Biophys; 2013 Mar; 65(2):187-95. PubMed ID: 22907585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.
    Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X
    Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic characteristics and development of embryos cloned from donor cells treated by trichostatin A or 5-aza-2'-deoxycytidine.
    Enright BP; Kubota C; Yang X; Tian XC
    Biol Reprod; 2003 Sep; 69(3):896-901. PubMed ID: 12748129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
    Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
    Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.